PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28373422
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer
      Cells.
PG  - 1617-1623
AB  - BACKGROUND/AIM: The survival rate of women diagnosed with triple-negative
      breast-cancer (TNBC) remains low. Hence, this study aimed at the chemical and
      biological optimization of furanosteroid derivatives for the treatment of this
      type of malignancy using TNBC cells. MATERIALS AND METHODS: Semi-synthetic
      analogs of wortmannolone (1-6) that negatively affected the aberrant pathways in 
      tumor cells were evaluated in hormone-independent breast cancer cells using
      western blot and cell-cycle analysis. RESULTS: Wortmannolone derivatization
      generated NF-kB inhibitors as new lead structures for further development.
      Compound (3) was found to be the most significantly active lead. CONCLUSION:
      Structure-activity analysis in the present study showed that acetylation of the
      hydroxyl groups and substitution on C3 and C17 of wortmannolone enhanced
      biological activity. Alpha-substitution of the acetyl group in C3 on ring A
      (compound 3) resulted in ROS inducing effect; however, presence of an acetyl
      group in beta-position of C3 displayed the highest NF-kB p65 inhibitory activity 
      (0.60 muM).
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Acuna, Ulyana Munoz
AU  - Acuna UM
AD  - Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State
      University, Columbus, OH, U.S.A.
AD  - Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio 
      State University, Columbus, OH, U.S.A.
FAU - Curley, Robert W Jr
AU  - Curley RW Jr
AD  - Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio 
      State University, Columbus, OH, U.S.A.
FAU - Fatima, Nighat
AU  - Fatima N
AD  - Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan.
AD  - Department of Pharmaceutical Sciences, Daniel K. Inouye College of Pharmacy,
      University of Hawaii at Hilo, Hilo, HI, U.S.A.
FAU - Ahmed, Safia
AU  - Ahmed S
AD  - Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan.
FAU - Chang, Leng Chee
AU  - Chang LC
AD  - Department of Pharmaceutical Sciences, Daniel K. Inouye College of Pharmacy,
      University of Hawaii at Hilo, Hilo, HI, U.S.A.
FAU - DE Blanco, Esperanza J Carcache
AU  - DE Blanco EJ
AD  - Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State
      University, Columbus, OH, U.S.A. [email protected]
AD  - Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio 
      State University, Columbus, OH, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Androstadienes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (NF-kappa B)
RN  - 0 (Reactive Oxygen Species)
RN  - XVA4O219QW (wortmannin)
SB  - IM
MH  - Androstadienes/*chemistry
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/*drug effects
MH  - Female
MH  - Humans
MH  - Immunoblotting
MH  - Immunosuppressive Agents/*chemistry
MH  - NF-kappa B/*antagonists & inhibitors/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Signal Transduction
MH  - Triple Negative Breast Neoplasms/drug therapy/metabolism/*pathology
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - *Furanosteroids
OT  - *K-Ras
OT  - *NF-kB p65
OT  - *ROS
OT  - *breast cancer cells
OT  - *wortmannolone
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/01/24 [received]
PHST- 2017/03/13 [revised]
PHST- 2017/03/14 [accepted]
AID - 37/4/1617 [pii]
AID - 10.21873/anticanres.11492 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1617-1623.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>